Do analysts prefer ITRM or PRPH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer PRPH or QLGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend ABP or PRPH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ABP or PRPH more profitable?

Abpro has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Abpro's return on equity of 0.00% beat ProPhase Labs' return on equity. Company Net Margins Return on Equity Return on Assets Abpro N/A N/A -344.76% ProPhase Labs -825.01% -482.05% -88.90%

Do analysts recommend PRPH or PPBT?

Purple Biotech has a consensus target price of $30.00, suggesting a potential upside of 1,968.97%. Given Purple Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Purple Biotech is more favorable than ProPhase Labs. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate JAGX or PRPH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jaguar Animal Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

ProPhase Labs (PRPH) Competitors

$0.07 +0.00 (+5.58%)

As of 12:34 PM Eastern

Compare

PRPH vs. ITRM, QLGN, ABP, PPBT, and JAGX

Should you buy ProPhase Labs stock or one of its competitors? MarketBeat compares ProPhase Labs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ProPhase Labs include Iterum Therapeutics (ITRM), Qualigen Therapeutics (QLGN), Abpro (ABP), Purple Biotech (PPBT), and Jaguar Animal Health (JAGX). These companies are all part of the "pharmaceutical products" industry.

How does ProPhase Labs compare to Iterum Therapeutics?

Iterum Therapeutics (NASDAQ:ITRM) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

Iterum Therapeutics has higher earnings, but lower revenue than ProPhase Labs. Iterum Therapeutics is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A
ProPhase Labs	$5.06M	0.19	-$53.36M	-$3.13	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are owned by institutional investors. 2.0% of Iterum Therapeutics shares are owned by company insiders. Comparatively, 9.6% of ProPhase Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Iterum Therapeutics has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Iterum Therapeutics' return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
ProPhase Labs	-825.01%	-482.05%	-88.90%

Iterum Therapeutics has a beta of 2.96, indicating that its share price is 196% more volatile than the broader market. Comparatively, ProPhase Labs has a beta of 0.06, indicating that its share price is 94% less volatile than the broader market.

In the previous week, ProPhase Labs had 1 more articles in the media than Iterum Therapeutics. MarketBeat recorded 1 mentions for ProPhase Labs and 0 mentions for Iterum Therapeutics. Iterum Therapeutics' average media sentiment score of 0.00 equaled ProPhase Labs'average media sentiment score.

Company	Overall Sentiment
Iterum Therapeutics	Neutral
ProPhase Labs	Neutral

Summary

Iterum Therapeutics beats ProPhase Labs on 8 of the 13 factors compared between the two stocks.

How does ProPhase Labs compare to Qualigen Therapeutics?

ProPhase Labs (NASDAQ:PRPH) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

9.4% of ProPhase Labs shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 9.6% of ProPhase Labs shares are owned by company insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Qualigen Therapeutics has lower revenue, but higher earnings than ProPhase Labs. Qualigen Therapeutics is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.06M	0.19	-$53.36M	-$3.13	N/A
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A

Qualigen Therapeutics has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Qualigen Therapeutics' return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
Qualigen Therapeutics	N/A	N/A	-202.16%

In the previous week, ProPhase Labs had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 1 mentions for ProPhase Labs and 0 mentions for Qualigen Therapeutics. ProPhase Labs' average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score.

Company	Overall Sentiment
ProPhase Labs	Neutral
Qualigen Therapeutics	Neutral

ProPhase Labs has a beta of 0.06, meaning that its share price is 94% less volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

Summary

ProPhase Labs beats Qualigen Therapeutics on 7 of the 11 factors compared between the two stocks.

How does ProPhase Labs compare to Abpro?

Abpro (NASDAQ:ABP) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Abpro has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Abpro's return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
ProPhase Labs	-825.01%	-482.05%	-88.90%

In the previous week, ProPhase Labs had 1 more articles in the media than Abpro. MarketBeat recorded 1 mentions for ProPhase Labs and 0 mentions for Abpro. Abpro's average media sentiment score of 0.00 equaled ProPhase Labs'average media sentiment score.

Company	Overall Sentiment
Abpro	Neutral
ProPhase Labs	Neutral

Abpro has higher earnings, but lower revenue than ProPhase Labs. Abpro is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
ProPhase Labs	$5.06M	0.19	-$53.36M	-$3.13	N/A

23.3% of Abpro shares are held by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are held by institutional investors. 13.7% of Abpro shares are held by insiders. Comparatively, 9.6% of ProPhase Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Abpro beats ProPhase Labs on 6 of the 11 factors compared between the two stocks.

How does ProPhase Labs compare to Purple Biotech?

ProPhase Labs (NASDAQ:PRPH) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Purple Biotech has a consensus target price of $30.00, suggesting a potential upside of 1,968.97%. Given Purple Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Purple Biotech is more favorable than ProPhase Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

ProPhase Labs has a beta of 0.06, suggesting that its stock price is 94% less volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

9.4% of ProPhase Labs shares are held by institutional investors. Comparatively, 9.6% of Purple Biotech shares are held by institutional investors. 9.6% of ProPhase Labs shares are held by insiders. Comparatively, 3.0% of Purple Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Purple Biotech has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Purple Biotech's return on equity of -123.63% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
Purple Biotech	N/A	-123.63%	-98.72%

In the previous week, ProPhase Labs had 1 more articles in the media than Purple Biotech. MarketBeat recorded 1 mentions for ProPhase Labs and 0 mentions for Purple Biotech. ProPhase Labs' average media sentiment score of 0.00 equaled Purple Biotech'saverage media sentiment score.

Company	Overall Sentiment
ProPhase Labs	Neutral
Purple Biotech	Neutral

Purple Biotech has lower revenue, but higher earnings than ProPhase Labs. Purple Biotech is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.06M	0.19	-$53.36M	-$3.13	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A

Summary

Purple Biotech beats ProPhase Labs on 8 of the 14 factors compared between the two stocks.

How does ProPhase Labs compare to Jaguar Animal Health?

Jaguar Animal Health (NASDAQ:JAGX) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

In the previous week, ProPhase Labs had 1 more articles in the media than Jaguar Animal Health. MarketBeat recorded 1 mentions for ProPhase Labs and 0 mentions for Jaguar Animal Health. Jaguar Animal Health's average media sentiment score of 0.00 equaled ProPhase Labs'average media sentiment score.

Company	Overall Sentiment
Jaguar Animal Health	Neutral
ProPhase Labs	Neutral

Jaguar Animal Health has a net margin of -169.04% compared to ProPhase Labs' net margin of -825.01%. Jaguar Animal Health's return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jaguar Animal Health	-169.04%	N/A	-115.55%
ProPhase Labs	-825.01%	-482.05%	-88.90%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jaguar Animal Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

12.0% of Jaguar Animal Health shares are owned by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are owned by institutional investors. 2.0% of Jaguar Animal Health shares are owned by company insiders. Comparatively, 9.6% of ProPhase Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Jaguar Animal Health has a beta of -0.11, meaning that its stock price is 111% less volatile than the broader market. Comparatively, ProPhase Labs has a beta of 0.06, meaning that its stock price is 94% less volatile than the broader market.

ProPhase Labs has lower revenue, but higher earnings than Jaguar Animal Health. ProPhase Labs is trading at a lower price-to-earnings ratio than Jaguar Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jaguar Animal Health	$11.51M	0.07	-$53.43M	-$591.92	N/A
ProPhase Labs	$5.06M	0.19	-$53.36M	-$3.13	N/A

Summary

ProPhase Labs beats Jaguar Animal Health on 7 of the 12 factors compared between the two stocks.

Get ProPhase Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRPH vs. The Competition

Export

Metric	ProPhase Labs	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$981K	$3.04B	$6.79B	$12.28B
Dividend Yield	N/A	2.05%	2.67%	9.36%
P/E Ratio	-0.02	20.20	27.10	23.96
Price / Sales	0.19	782.84	573.91	112.12
Price / Cash	N/A	27.11	26.68	47.27
Price / Book	0.03	4.20	10.66	6.14
Net Income	-$53.36M	$65.94M	$3.60B	$331.74M
7 Day Performance	N/A	-3.04%	-1.51%	-1.72%
1 Month Performance	N/A	-1.30%	1.11%	-1.44%
1 Year Performance	N/A	16.06%	23.77%	16.97%

ProPhase Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRPH ProPhase Labs	0.074 of 5 stars	$0.07 +5.6%	N/A	-98.2%	$981K	$5.06M	N/A	130	Gap Up
ITRM Iterum Therapeutics	N/A	$0.03 flat	N/A	N/A	$1.60M	$390K	N/A	10
QLGN Qualigen Therapeutics	N/A	$0.92 -9.8%	N/A	-74.2%	$1.56M	N/A	N/A	50	Gap Down
ABP Abpro	N/A	$0.52 flat	N/A	N/A	$1.42M	N/A	N/A	15
PPBT Purple Biotech	3.0184 of 5 stars	$1.41 -7.2%	$30.00 +2,027.7%	-94.3%	$1.31M	N/A	N/A	20	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRPH) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ProPhase Labs (PRPH) Competitors

PRPH vs. ITRM, QLGN, ABP, PPBT, and JAGX

How does ProPhase Labs compare to Iterum Therapeutics?

Summary

How does ProPhase Labs compare to Qualigen Therapeutics?

Summary

How does ProPhase Labs compare to Abpro?

Summary

How does ProPhase Labs compare to Purple Biotech?

Summary

How does ProPhase Labs compare to Jaguar Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRPH vs. The Competition

ProPhase Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ProPhase Labs (PRPH) Competitors

PRPH vs. ITRM, QLGN, ABP, PPBT, and JAGX

How does ProPhase Labs compare to Iterum Therapeutics?

Which has stronger valuation and earnings, ITRM or PRPH?

Do analysts prefer ITRM or PRPH?

Do insiders and institutionals believe in ITRM or PRPH?

Is ITRM or PRPH more profitable?

Which has more risk and volatility, ITRM or PRPH?

Does the media favor ITRM or PRPH?

Summary

How does ProPhase Labs compare to Qualigen Therapeutics?

Do insiders & institutionals hold more shares of PRPH or QLGN?

Do analysts prefer PRPH or QLGN?

Which has stronger valuation and earnings, PRPH or QLGN?

Is PRPH or QLGN more profitable?

Does the media prefer PRPH or QLGN?

Which has more risk & volatility, PRPH or QLGN?

Summary

How does ProPhase Labs compare to Abpro?

Is ABP or PRPH more profitable?

Does the media refer more to ABP or PRPH?

Which has preferable earnings & valuation, ABP or PRPH?

Do insiders and institutionals believe in ABP or PRPH?

Do analysts recommend ABP or PRPH?

Summary

How does ProPhase Labs compare to Purple Biotech?

Do analysts recommend PRPH or PPBT?

Which has more volatility and risk, PRPH or PPBT?

Do institutionals and insiders have more ownership in PRPH or PPBT?

Is PRPH or PPBT more profitable?

Does the media refer more to PRPH or PPBT?

Which has stronger earnings & valuation, PRPH or PPBT?

Summary

How does ProPhase Labs compare to Jaguar Animal Health?

Does the media favor JAGX or PRPH?

Is JAGX or PRPH more profitable?

Do analysts rate JAGX or PRPH?

Do institutionals & insiders have more ownership in JAGX or PRPH?

Which has more risk and volatility, JAGX or PRPH?

Which has better earnings and valuation, JAGX or PRPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRPH vs. The Competition

ProPhase Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools